NUTRICIA FOUNDATION
To assess the effects of a low-FODMAP diet compared with a regular balanced diet for the management of children with IBS
On the Polish market, there is a pleuran preparation with the addition of vitamin C and probiotic bacteria strains recommended by manufacturers for use during acute diarrhea in children and adults. So far, there is no scientific evidence to support its effectiveness in alleviating symptoms or shortening the duration of the disease. Considering the potential immunomodulatory effects of pleuran, it seems justified to investigate its efficacy in the treatment of acute diarrhea in children. The aim of this study is to evaluate the effect of pleuran on the duration and intensity of symptoms of acute infectious diarrhea in children.
Patients with mild to moderate AP will be randomized to groups: A - refeeding within 24 hours from the hospital admission, B - refeeding after 24 hours from the hospital admission. The patient will be able to choose low fat and low-fiber products and meals. Proinflammatory cytokines and zonulin levels will be assessed at the day 0, S and 5 of hospitalization and at the day of hospital discharge.
The aim of the project is to investigate the effect of iron supplementation in healthy breastfed infants on psychomotor development up to the age of 3. The expected results of the study will be published in peer-reviewed journals in the field of child nutrition and will have a potential impact on the development of infant nutrition guidelines.
Aims of the study 1. Assessment of feeding difficulties according to the Montreal Children's Hospital Feeding Scale (MCHFD) in children allergic to cow's milk protein on a dairy-free diet. 3. Anthropometric assessment of nutritional status in children allergic to cow's milk protein on a dairy-free diet. Methodology cross-sectional, multi-center study. Location of the study. Allergy and gastroenterological clinics in Warsaw, Bydgoszcz, Białystok, Kraków, Olsztyn, Gdańsk, Katowice, coordination: Department of Paediatrics, Medical University of Warsaw. Inclusion criteria: Term-born children aged 6 months - 2 years on an elimination diet for at least 1 month. Written consent to participate in the study. Exclusion criteria Chronic diseases leading to nutritional impairment Endpoints: 1. Percentage of children with nutritional disorders defined as: Weight/height <-2 z-score (moderate nutritional impairment) Weight/height <-1 z-score (mild impairment) nutritional status) Weight/height> -1 z-score (risk of obesity) Weight/height> -2 z-score (obesity) And: BMI <-2 zscore (moderate nutritional impairment) BMI <-1 zscore (mildly impaired nutrition) BMI> -1 zscore (risk of obesity) BMI> -2 zscore (obesity) 2. Percentage of children with feeding difficulties according to the Montraal Children's Hospital Feeding Directory. Calculated size of the studied group: 352
Current research suggests that the interaction between the gut microflora and the immune system may be a factor in the development of type 1 diabetes. Changes in the composition of the gut microflora observed in patients with type 1 diabetes may increase intestinal permeability. Greater exposure to the immune system of food antigens and microbiota-derived products may cause a pro-inflammatory response and stimulate beta-cell autoimmunity in genetically predisposed individuals. The aim of the study is to assess whether the supplementation of probiotic bacteria Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 has a positive effect on the function of pancreatic beta cells in children with newly diagnosed type 1 diabetes. Expected results: The results of this randomized controlled trial, both positive and negative, will lead to further recommendations on the use of Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 to improve beta cell function in children with newly diagnosed type 1 diabetes. Primary endpoint: areas under the curve the level of the C-peptide of the peptide after stimulation. Secondary endpoints: fasting C-peptide concentration, insulin requirement, HbA1c, interleukins, intestinal permeability, anthropometric parameters, side effects, occurrence of other autoimmune diseases, acute diabetes complications. The protocol has been registered ClinicalTrials.gov. NCT03032354 and published BMJ Open. 2017 Oct 11;7(10):e017178. doi: 10.1136/bmjopen-2017-017178.